新华医疗
(600587)
| 流通市值：103.77亿 | | | 总市值：104.17亿 |
| 流通股本：6.04亿 | | | 总股本：6.07亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,790,414,888.01 | 2,307,531,823.28 | 10,020,618,625.09 | 7,423,276,804.99 |
| 营业收入 | 4,790,414,888.01 | 2,307,531,823.28 | 10,020,618,625.09 | 7,423,276,804.99 |
| 二、营业总成本 | 4,397,550,992.73 | 2,149,307,245.87 | 9,224,340,970.06 | 6,773,832,366.13 |
| 营业成本 | 3,582,676,003.81 | 1,758,644,239.58 | 7,409,687,368.01 | 5,469,945,360.84 |
| 税金及附加 | 33,170,450.39 | 14,799,018.49 | 68,778,820.95 | 50,843,853.06 |
| 销售费用 | 387,744,638.85 | 191,574,663.62 | 868,611,725.72 | 641,583,248.14 |
| 管理费用 | 178,062,225.44 | 84,486,138.45 | 422,075,778.52 | 301,150,902.47 |
| 研发费用 | 201,713,769.93 | 93,857,263.18 | 436,083,724.78 | 297,141,310.8 |
| 财务费用 | 14,183,904.31 | 5,945,922.55 | 19,103,552.08 | 13,167,690.82 |
| 其中:利息费用 | 21,348,494.52 | 10,844,514.18 | 44,793,595.87 | 33,851,006.57 |
| 其中:利息收入 | -9,225,075.47 | 5,063,781.89 | 24,744,881.82 | 20,692,553.27 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 52,113,996.21 | 11,590,440.94 | 70,823,343.99 | 52,663,544.58 |
| 资产处置收益 | -837,997.31 | -926,811.97 | 598,273.43 | 201,219.26 |
| 资产减值损失(新) | -14,253,517.71 | 2,504,021.98 | -70,302,431.87 | -10,341,512.28 |
| 信用减值损失(新) | -11,340,053.6 | -2,168,131.48 | -84,244,609.03 | -15,751,765.75 |
| 其他收益 | 36,093,544.73 | 21,026,349.59 | 85,364,820.68 | 50,225,227.23 |
| 四、营业利润 | 454,639,867.6 | 190,250,446.47 | 798,517,052.23 | 726,441,151.9 |
| 加:营业外收入 | 2,699,995.21 | 688,877.89 | 9,728,381.99 | 4,200,855.35 |
| 减:营业外支出 | 2,862,993.27 | 970,574.69 | 12,584,131.6 | 6,561,548.89 |
| 五、利润总额 | 454,476,869.54 | 189,968,749.67 | 795,661,302.62 | 724,080,458.36 |
| 减:所得税费用 | 64,085,293.87 | 28,741,160.67 | 103,764,322.5 | 90,127,083.71 |
| 六、净利润 | 390,391,575.67 | 161,227,589 | 691,896,980.12 | 633,953,374.65 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 390,391,575.67 | 161,227,589 | 691,896,980.12 | 633,953,374.65 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 385,717,607.04 | 160,455,800.07 | 691,609,558.03 | 617,001,476.94 |
| 少数股东损益 | 4,673,968.63 | 771,788.93 | 287,422.09 | 16,951,897.71 |
| 扣除非经常损益后的净利润 | 332,742,127.52 | 157,702,901.57 | 623,195,651.23 | 607,069,625.4 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.64 | 0.27 | 1.14 | 1.17 |
| (二)稀释每股收益 | 0.64 | 0.27 | 1.14 | 1.17 |
| 八、其他综合收益 | -3,094,830.46 | - | 3,526,890.99 | 62,894.13 |
| 归属于母公司股东的其他综合收益 | -3,094,830.46 | - | 3,526,890.99 | 62,894.13 |
| 九、综合收益总额 | 387,296,745.21 | 161,227,589 | 695,423,871.11 | 634,016,268.78 |
| 归属于母公司股东的综合收益总额 | 382,622,776.58 | 160,455,800.07 | 695,136,449.02 | 617,064,371.07 |
| 归属于少数股东的综合收益总额 | 4,673,968.63 | 771,788.93 | 287,422.09 | 16,951,897.71 |
| 公告日期 | 2025-08-29 | 2025-04-30 | 2025-04-30 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |